In the pembrolizumab arms, the median PFS was 3.8 months in BRAF wild-type melanoma patients versus 2.8 months in BRAF-mutant melanoma patients; the 6-month PFS rate was 40.9% versus 19.5%, with an ORR of 26.7% vs. 11.9%, respectively [41]. This evidence concerns the gene BRAF and melanoma.